Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Acquires Avenue, Primes Play In Pain Amid US Opioid Crisis

Executive Summary

Cipla has struck a 'de-risked' deal to acquire the specialty firm Avenue Therapeutics, Inc, for up to $215m as it readies a niche play in the US pain management segment amid the opioid crisis.

You may also be interested in...



Cipla To Recalibrate US Investments

Cipla is to moderate investments across its US generics R&D and specialty business, while its India business components  prescription, trade generic and consumer health  are being brought under a “single capital allocation framework.”

Cipla To Recalibrate US Investments, Partnering Plan For Specialty Business

Cipla to moderate investments across US generics R&D and specialty business, while its India business components - prescription, trade generic and consumer health - are being brought under a “single capital allocation framework.”

Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT126735

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel